July 02, 2026

Does Structured Reporting Improve Lung Cancer Reports?

A structured reporting tool improved report completeness, reduced classification errors, and achieved high physician adoption during routine lung cancer pathology reporting.

Conexiant

July 01, 2026

FDA Approves Treg Cell Therapy

A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.

Conexiant

June 26, 2026

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.

Conexiant

June 23, 2026

HHS Announces Department-Wide Clinical Trial Initiative

Agency-wide effort targets US clinical trial timelines, enrollment, and regulatory barriers.

Conexiant

June 19, 2026

Most Miss Streamlined Neck Mass Dx Path

Same-visit biopsy and fewer empiric workup steps were linked to faster pathologic diagnosis in a retrospective analysis.

Conexiant

June 18, 2026

Cell Aging May Predict Future Disease

Plasma proteomic models of more than 40 cell types were associated with incident Alzheimer's disease, amyotrophic lateral sclerosis, cancer,  and mortality across three large cohorts.

Conexiant

June 02, 2026

Consensus Guidance May Improve Sinonasal Mass Outcomes

Multidisciplinary recommendations emphasize biopsy technique, imaging, and pathology review in patients with suspected sinonasal malignancy.

Conexiant

June 01, 2026

Can Proteomics Refine Lung Screening?

Proteomic biomarkers improve short-term lung cancer risk assessment.

Conexiant

May 29, 2026

AI Shows Promise for Intraoperative Lung Adenocarcinoma Assessment

A smartphone image–centered deep learning model showed promise for intraoperative diagnosis and grading of clinical stage IA lung adenocarcinoma, but grade-specific limitations and lack of outcomes data mean the tool remains investigational.

Conexiant

May 20, 2026

FDA Approves Expanded Liquid Biopsy Panel

Updated liquid biopsy combines genomic and epigenomic profiling for companion diagnostic use across multiple tumor types.

Conexiant